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To the editor:
The paper by Friesenbichler and colleagues [2] reported
the findings of a truncated clinical study involving 31
patients treated for bone tumors by curettage, and filling of
the defect using geneX1 (Biocomposites Ltd., Staffordshire,
UK).
‘‘The reconstructive approach after intralesional curet-
tage is controversial and clinical practice varies,’’ the authors
reported. ‘‘Polymethylmethacrylate (PMMA), allografts or
autografts have been used in several studies and complica-
tion rates up to 33% have been reported’’ [2].
The authors reported the use of geneX1 in 31 patients,
of which 26 patients had no complications. Based on these
figures alone, these data represent a 16% complication rate
— less than the 33% quoted above when using allografts
and autografts.
Two patients (Patients 21 and 30) developed a post-
operative soft tissue cyst at 52 and 55 days respectively,
which reduced in size within 2 months without surgical
intervention. One of these patients (Patient 30) also
received an allograft and a Vitoss1 Bone Graft Sub-
stitute from Stryker Orthopaedics (Mahwah, NJ, USA)
— a fact not reported in this article. In accordance with
the medical device regulations, an investigation and visit
by our regulatory department was carried out. This visit
revealed the concurrent use of Vitoss1 in one of the
cases.
Three patients (Patients 2, 25, and 31) had postoperative
aseptic inflammation. One of the patients, a 14-year-old
juvenile identified as a worst case, also received allograft.
This patient required revision surgery 1 month after sur-
gery, and presented with severe damage to the skin.
Histology showed a chronic, lymphocytic inflammation
with plasma cells. It is questionable to attribute these
adverse reactions to the presence of geneX1 alone con-
sidering the concurrent use of allograft.
The authors believed one of the reasons for the inflam-
mation and soft tissue cyst formation was the overfilled and
pressurized defect site when using allografts. The Instruc-
tions For Use for geneX1 advise against overfilling or
pressurizing the treatment site, and also recommend not
adding other substances to the product.
To conclude that this type of bone substitute should not
be used in the treatment of bony defects as a result of these
data would appear presumptuous, and not warranted on the
strength of the outcomes.
The comments made regarding the Saadoun paper [3]
would suggest that the authors did not read the published
response [1] or the clarification statement subsequently
published by the authors [4]. geneX1 is cleared as a Class
II medical device by the FDA, CE marked in accordance
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A Publication of  The Association of Bone and Joint Surgeons®
with the Medical Devices Directive 93/42/EEC, and com-
plies with all safety and biocompatibility requirements.
Since its launch in 2004, more than 20,000 packs of ge-
neX1 have been used worldwide, and fewer than 0.24%
reported complaints, according to our internal records
(Procedure QAP0018).
geneX1 is safe and an effective bone void filler when
used in accordance with the Instructions For Use.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Fitzer S, Cooper JJ. Biocomposites Ltd response. J Neurol
Neurosurg Psychiatry. 2011;82:e3.
2. Friesenbichler J, Maurer-Ertl W, Sadoghi P, Pirker-Fruehauf U,
Bodo K, Leithner A. Adverse Reactions of Artificial Bone Graft
Substitutes: Lessons Learned From Using Tricalcium Phosphate
geneX1. [Published online ahead of print September 28, 2013].
Clin Orthop Relat Res. DOI: 10.1007/s11999-013-3305-z.
3. Saadoun S, Macdonald C, Bell BA, Papadopoulos MC. Dangers of
bone graft substitutes: lessons from using geneX1. J Neurol
Neurosurg Psychiatry. 2011;82:e3.
4. Saadoun S, Macdonald C, Bell BA, Papadopoulos MC. Dangers of
bone graft substitutes: lessons from using geneX1. Clarification. J
Neurol Neurosurg Psychiatry. 2011;82:e3.
766 Laycock and Cooper Clinical Orthopaedics and Related Research1
123
